Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EBITDA per Employee

The EBITDA per Employee of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 24, 2026 is 1.50 M CNY. In the previous year, EBITDA per Employee was 1.94 M CNY — a change of -22.66% (lower).

EBITDA per Employee

1.50 MCNY

YoY

-22.66%

Last updated:

EBITDA per Employee of Tibet Rhodiola Pharmaceutical Holding is 2025 1.50 M CNY. EBITDA per Employee of Tibet Rhodiola Pharmaceutical Holding was 2024 1.94 M CNY. It decreases by -22.66% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
403,665.69 CNY
Jan 1, 2019
582,153.33 CNY
Jan 1, 2020
778,077.12 CNY
Jan 1, 2021
441,189.48 CNY
Jan 1, 2022
804,648.91 CNY
Jan 1, 2023
1.50 M CNY
Jan 1, 2024
1.94 M CNY
Jan 1, 2025
1.50 M CNY
The Tibet Rhodiola Pharmaceutical Holding EBITDA per Employee history
YEAREBITDA per EmployeeYoY
1.50 MCNY-22.66%
1.94 MCNY+29.24%
1.50 MCNY+86.94%
804,648.91CNY+82.38%
441,189.48CNY-43.30%
778,077.12CNY+33.66%
582,153.33CNY+44.22%
403,665.69CNY+14.41%
352,810.94CNY+7.26%
328,918.54CNY+77.68%
185,117.41CNY+253.11%
52,425.12CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EBITDA per Employee of Tibet Rhodiola Pharmaceutical Holding is 1.50 M CNY in 2025.

EBITDA per Employee of Tibet Rhodiola Pharmaceutical Holding changed from 1.94 M CNY to 1.50 M CNY, representing a -22.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Tibet Rhodiola Pharmaceutical Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding